INVO Bioscience stock (US44984F1049): Trading at $2.77 amid low-volume sessions

INVO Bioscience (NASDAQ:IVF) shares recently ranged between $1.55 and $2.77, with average daily volume at 41,847 shares and a market cap of $2.55 million, according to MarketBeat data as of recent trading.

INVO Bioscience, trading as IVF on Nasdaq, showed a 52-week range of $1.55 to $2.77 with recent volume at 21,405 shares versus an average of 41,847, reflecting a market capitalization of $2.55 million, MarketBeat as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: INVO Bioscience Inc
• Sector/industry: Medical / Surgical & medical instruments
• Headquarters/country: United States
• Core markets: Assisted reproductive technologies
• Key revenue drivers: INVOcell device sales
• Home exchange/listing venue: Nasdaq (IVF)
• Trading currency: USD

INVO Bioscience: core business model

INVO Bioscience develops and commercializes devices for in-vivo fertilization and early embryo development inside the patient's body, offering an alternative to traditional lab-based IVF. The flagship INVOcell device facilitates natural incubation, aiming to reduce costs and improve accessibility in fertility treatments. Founded in 2009 with 10 employees, the company focuses on medical technology innovation in reproductive health, MarketBeat company overview as of May 2026.

This approach contrasts with conventional in vitro methods by leveraging the body's environment, potentially lowering expenses for clinics and patients. INVO targets underserved markets where affordability is key, positioning itself in the growing assisted reproductive sector.

Main revenue and product drivers for INVO Bioscience

Primary revenue stems from sales of the INVOcell system, a disposable intravaginal culture device cleared for use in fertility procedures. The company reported trailing twelve-month revenue of $3.15 million alongside a net loss of $9.10 million and margins at -417%, per recent financial summaries published with data through early 2026, MarketBeat financials as of May 2026.

Key drivers include expansion into international clinics and partnerships for device distribution. With return on assets at -92.42%, the firm relies on product adoption and potential regulatory approvals to scale operations.

Industry trends and competitive position

The surgical and medical instruments industry, particularly fertility tech, sees demand from rising infertility rates and tech advancements. INVO competes with larger players but differentiates via cost-effective in-vivo solutions. Institutional ownership stands at 12%, higher than some peers like Quoin Pharmaceuticals at 8.6%, MarketBeat competitors as of May 2026.

Why INVO Bioscience matters for US investors

Listed on Nasdaq, INVO offers US investors exposure to the $20+ billion fertility market, with innovations addressing accessibility amid demographic shifts like delayed childbearing. Its micro-cap status provides potential upside in biotech growth, relevant for portfolios tracking medtech disruptors.

Conclusion

INVO Bioscience continues to innovate in affordable fertility solutions with its INVOcell technology, trading at low volumes on Nasdaq amid a $2.55 million market cap. Recent ranges and financials highlight challenges like negative margins, yet the firm's niche in reproductive medtech holds relevance for US investors eyeing biotech. Ongoing clinic adoptions and market trends will shape its path forward.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.